Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSG vs PM vs SSG+PM for Visceral Leishmaniasis
NCT00255567Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Nov 2004
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of paromomycin in visceral leishmaniasis (VL) (3 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Parasitological Clearance at 6 months. Started Nov 2004; status: completed.
02
Drugs
paromomycin
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT00255567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00255567.